Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series

This study assessed the efficacy and tolerability of Brevilin-A, a natural JAK inhibitor, in 15 pediatric patients with mild-moderate alopecia areata over 6 months. Patients applied a topical lotion containing Brevilin-A, leading to significant hair regrowth and improved quality of life, with 46.7% achieving complete lesion resolution and 33.3% showing partial improvement. No significant adverse events were reported. Despite the small sample size and absence of a control group, Brevilin-A shows promise as a treatment for recalcitrant alopecia areata in children, potentially offering an alternative to traditional therapies with fewer side effects. Further research is needed to confirm these findings.